Cargando…
New Approach of Anti-VEGF Agents for Age-Related Macular Degeneration
Age-related macular degeneration (AMD) is the leading cause of visual loss in older population. Angiogenesis is an important factor associated with the development of CNV due to AMD. Treatment of CNV with intravitreal anti-VEGF monotherapy is currently the standard of care. However, not all patients...
Autores principales: | Park, Young Gun, Rhu, Hyun Wook, Kang, Seungbum, Roh, Young Jung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3307057/ https://www.ncbi.nlm.nih.gov/pubmed/22496964 http://dx.doi.org/10.1155/2012/637316 |
Ejemplares similares
-
Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
por: Kaiser, Stephanie M, et al.
Publicado: (2021) -
Retinal layers changes in patients with age-related macular degeneration treated with intravitreal anti-VEGF agents
por: Zhou, Dan, et al.
Publicado: (2023) -
Anti-VEGF Agents for the Treatment of Pigment Epithelial Detachments Associated with Neovascular Age-related Macular Degeneration: An Evidence-based Approach
por: Panos, Georgios D., et al.
Publicado: (2015) -
Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration
por: García-Quintanilla, Laura, et al.
Publicado: (2019) -
Application and mechanism of anti-VEGF drugs in age-related macular degeneration
por: Song, Dawei, et al.
Publicado: (2022)